GIST Mutation Detection Kit Market
Report ID: SQMIG35J2752
Report ID: SQMIG35J2752
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35J2752 |
Region:
Global |
Published Date: August, 2026
Pages:
157
|Tables:
119
|Figures:
77
Global Gist Mutation Detection Kit Market size was valued at USD 478.0 Million in 2024 and is poised to grow from USD 529.15 Million in 2025 to USD 1193.32 Million by 2033, growing at a CAGR of 10.7% during the forecast period (2026-2033).
The global GIST mutation detection kit market comprises molecular diagnostic products that identify KIT and PDGFRA alterations in gastrointestinal stromal tumors, enabling personalized therapy selection. Its significance lies in the ability to match patients with tyrosine‑kinase inhibitors, thereby improving survival and reducing unnecessary toxicity. Since the early 2000s, when PCR‑based assays first entered clinical labs, the market has expanded from niche research tools to widely adopted companion diagnostics driven by regulatory approvals of imatinib and subsequent agents. The primary driver today is the prevalence of precision‑oncology guidelines, which compel oncologists to perform molecular profiling at diagnosis, thereby creating sustained demand for rapid kits.
Another key trend driving the global GIST mutation detection kit sector is the integration of next‑generation sequencing panels that include GIST assays, giving clinicians broader mutational insight while keeping costs low. As hospitals adopt multiplex platforms, labs replace single‑gene kits with broader solutions, prompting vendors to produce kits compatible with automated workflows and liquid‑biopsy samples. This shift opens opportunities for emerging players to capture share by serving settings where tissue is scarce, as shown by pilot programs in Southeast Asia that use plasma kits to guide therapy. Consequently, demand for versatile GIST detection kits will rise sharply, spurring R&D investment and widening the market in the coming years.
How is AI Improving Accuracy in the Gist Mutation Detection Kit Market?
Artificial intelligence is reshaping the GIST mutation detection kit market by enhancing data interpretation, reducing error rates, and streamlining workflow. Key aspects include machine‑learning algorithms that recognize subtle sequence variations, automated quality‑control checks that flag low‑confidence calls, and cloud‑based platforms that aggregate results for rapid clinical review. The current state sees most vendors pairing next‑generation sequencing panels with AI software to deliver consistent, high‑resolution mutation profiles. This shift is driven by clinicians’ need for reliable diagnostics in a landscape where precise KIT and PDGFRA identification guides targeted therapy. Early adopters report smoother laboratory operations and more confident treatment decisions, making the market increasingly competitive.
In 2025, QIAGEN expanded the use of AI-powered genomic interpretation through its QIAGEN Clinical Insights platform, which uses AI-assisted curation to analyze large volumes of scientific literature and identify relevant genomic findings. This development can indirectly support GIST mutation detection by accelerating interpretation of tumor mutations and helping clinicians connect detected variants with actionable precision-oncology treatment decisions.
Market snapshot - (2026-2033)
Global Market Size
USD 478.0 Million
Largest Segment
PCR-Based Kits
Fastest Growth
Next-Generation Sequencing (NGS) Kits
Growth Rate
10.7% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global gist mutation detection kit market is segmented by technology, mutation type, end user, application and region. Based on technology, the market is segmented into PCR-based kits, next-generation sequencing (NGS) kits, sanger sequencing kits and other molecular technologies. Based on mutation type, the market is segmented into KIT gene mutation detection, PDGFRA gene mutation detection and multi-gene mutation detection. Based on end user, the market is segmented into hospitals, diagnostic laboratories, cancer research institutes and pharmaceutical & biotechnology companies. Based on application, the market is segmented into clinical diagnosis, treatment selection and research use. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
As per the global GIST mutation detection kit market growth, PCR-based kits segment dominates because it offers rapid turnaround, high sensitivity, and cost efficiency that align with clinical workflows. Laboratories favor these kits for detecting single‑gene alterations such as KIT and PDGFRA, where amplification is critical. The technology’s ease of use reduces training requirements and minimizes equipment investment, making it the preferred choice for testing. Consequently, its reliability and affordability drive widespread adoption across the GIST mutation detection kit market.
Meanwhile, next-generation sequencing kits emerge as a rapidly expanding sub‑segment, propelled by the rising need for comprehensive genomic profiling in GIST patients. Their ability to simultaneously assess multiple mutations accelerates personalized therapy decisions, prompting laboratories to invest in advanced platforms. This innovation fuels market expansion and creates new opportunities for diagnostics.
Diagnostic laboratories segment dominates because they handle most GIST mutation testing, integrating kits into routine workflows to support clinical decisions. Their infrastructure, specialized staff, and demand for reliable solutions drive preference for validated kits. The need to meet accreditation standards and reimbursements further reinforces reliance on trusted providers, cementing their leading role in shaping market dynamics. Their capacity to process sample volumes and deliver result turnaround also attracts clinicians seeking efficient diagnostic pathways.
Conversely, cancer research institutes segment is witnessing the strongest growth as academic labs pursue extensive genomic studies on GIST. Their focus on multi‑gene panels and exploratory research drives demand for flexible kits that support novel biomarker discovery. This scholarly emphasis fuels market diversification and stimulates innovation pipelines, expanding future opportunities.
To get detailed segments analysis, Request a Free Sample Report
As per the global GIST mutation detection kit market share, North America retains a leading position in the industry because of a mature healthcare infrastructure, strong research ecosystems, and early adoption of precision oncology tools. The United States hosts a concentration of biotech innovators and academic centers that continuously advance assay design, while regulatory pathways are well‑established, allowing swift market entry. Canada contributes by integrating advanced diagnostics into publicly funded health systems, fostering widespread clinical uptake. Significant private and public investment fuels continual improvements in kit sensitivity and workflow automation, while a deep talent pool of molecular pathologists and bioinformaticians accelerates translation of research findings into routine testing. Moreover, strong patient advocacy groups promote awareness of GIST molecular profiling, encouraging clinicians to incorporate mutation detection kits as standard of care, thereby sustaining market leadership.
GIST mutation detection kit market in the United States benefits from a convergence of cutting‑edge biotech startups, leading academic hospitals, and a regulatory environment that encourages rapid clinical validation. Extensive collaborations between diagnostic manufacturers and pharmaceutical firms streamline kit integration into treatment pathways, while reimbursement policies support widespread adoption across both private and public healthcare systems. This ecosystem drives consistent demand for high‑performance mutation detection solutions and reliable applications.
GIST mutation detection kit market in Canada is reinforced by universal healthcare coverage that prioritizes evidence‑based diagnostics, enabling prompt incorporation of advanced kits into provincial oncology programs. Strong ties between research universities and diagnostic firms foster innovation tailored to the Canadian clinical setting, while collaborative funding mechanisms reduce financial barriers for laboratories adopting new technologies. This supportive framework sustains steady nationwide growth and broad clinical reach for mutation detection kits.
Based on global GIST mutation detection kit regional forecast, Europe is witnessing rapid expansion of the industry driven by coordinated healthcare strategies, strong academic‑clinical partnerships, and an emphasis on personalized medicine across member states. The region’s extensive network of specialized cancer centers accelerates validation of multiplexed kits, while regulatory harmonization through EU frameworks simplifies cross‑border product deployment. Investment in genomic research infrastructure, coupled with reimbursement schemes that recognize the clinical value of molecular profiling, encourages laboratories to upgrade their testing capabilities. Additionally, patient advocacy groups and professional societies actively promote awareness of GIST genetic testing, stimulating clinician demand. The culture among European biotech firms and diagnostic manufacturers fosters iteration of assay designs, ensuring kits remain aligned with therapeutic targets. Moreover, national health technology assessment bodies increasingly endorse mutation testing as a cost‑effective strategy to guide treatment, further cementing the market’s upward trajectory.
GIST mutation detection kit market in Germany is anchored by a robust network of university hospitals that serve as reference centers for rare sarcomas. Continuous funding for molecular pathology programs enables laboratories to adopt next‑generation detection kits, while national reimbursement policies reward precise genomic testing. Close collaboration between diagnostic firms and pharmaceutical companies targeting GIST therapies accelerates kit validation, ensuring that clinical labs have access to reliable, high‑throughput solutions.
GIST mutation detection kit market in the United Kingdom experiences growth driven by the nation’s emphasis on cancer pathways and early adoption of genomic medicine. Leading cancer research institutes partner closely with diagnostic manufacturers to co‑develop kits that meet NHS clinical guidelines, while reimbursement mechanisms encourage widespread use across public hospitals. The strong presence of specialist sarcoma centers further propels demand for precise mutation detection, positioning the UK as a dynamic hub for market expansion.
GIST mutation detection kit market in France is emerging as molecular oncology gains traction within the national health system. Investment in regional cancer genomics platforms encourages hospitals to incorporate comprehensive mutation kits into diagnostic algorithms. Collaborative initiatives between French biotech firms and university laboratories facilitate adaptation of kits to local regulatory standards, while reimbursement strategies increasingly cover targeted testing for sarcoma patients. This supportive environment gradually expands the use of GIST mutation detection across French clinical practice.
As per global GIST mutation detection kit regional outlook, Asia Pacific is steadily strengthening its position in the industry through a combination of rapidly evolving healthcare infrastructure, increasing focus on precision oncology, and burgeoning biotech ecosystems in key economies. The region benefits from significant government initiatives that fund genomic research and encourage integration of molecular diagnostics into cancer care pathways. Growing awareness among clinicians of the therapeutic relevance of GIST mutations drives demand for reliable detection kits, while private‑sector investment accelerates the development of locally adapted assay platforms. Collaborative networks linking academic research centers with diagnostic manufacturers foster technology transfer and capacity building, ensuring that kit performance meets both regional clinical needs and international quality standards. These synergistic forces collectively enhance the region’s capability to capture a larger share of the global market.
GIST mutation detection kit market in Japan is propelled by an advanced diagnostic landscape where leading oncology hospitals adopt cutting‑edge molecular testing as standard practice. Strong governmental support for precision medicine programs encourages hospitals to integrate comprehensive GIST mutation kits into routine workflows. Partnerships between Japanese biotech innovators and global manufacturers enable technology transfer, resulting in kits that align with local regulatory requirements while maintaining high analytical performance. This environment sustains robust clinical adoption and positions Japan as a benchmark for quality in the Asia Pacific region.
GIST mutation detection kit market in South Korea is gaining momentum as national cancer programs prioritize genomic profiling for targeted therapy decisions. The country’s well‑established network of tertiary care centers facilitates rapid implementation of mutation detection kits, while collaborative research initiatives between Korean universities and diagnostic firms drive customization of assays to local patient populations. Reimbursement policies increasingly recognize the clinical value of GIST testing, encouraging broader uptake across both public and private hospitals. Consequently, South Korea is emerging as a dynamic contributor to the region’s overall market advancement.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Growing Use of Targeted Therapies
Adopting Molecular Diagnostic Platforms
High Cost of Advanced Kits
Regulatory Hurdles in Clinical Deployment
Request Free Customization of this report to help us to meet your business objectives.
The global GIST mutation detection kit market outlook is competitive, with QIAGEN, Thermo Fisher Scientific, Bio-Rad Laboratories, AmoyDx, and EntroGen as key international players. QIAGEN focuses on companion diagnostics and targeted mutation testing, while Thermo Fisher Scientific leverages next-generation sequencing and molecular diagnostic technologies. AmoyDx emphasizes targeted cancer mutation detection, whereas Bio-Rad strengthens its position through sensitive molecular testing platforms and workflow solutions for precision oncology applications.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis the global GIST mutation detection kit industry is expanding at a healthy pace driven primarily by the growing use of targeted therapies that require rapid and reliable molecular profiling, while the rising adoption of molecular diagnostic platforms further fuels demand by enabling high‑throughput automated testing. PCR‑Based kits lead the segment landscape thanks to their speed, sensitivity and cost‑effectiveness, and North America remains the dominant region supported by a mature healthcare infrastructure and strong precision‑oncology adoption. However, the high cost of advanced kits poses a restraint, limiting uptake in smaller laboratories and emerging markets despite the overall favorable outlook.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 478.0 Million |
| Market size value in 2033 | USD 1193.32 Million |
| Growth Rate | 10.7% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the GIST Mutation Detection Kit Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the GIST Mutation Detection Kit Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the GIST Mutation Detection Kit Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the GIST Mutation Detection Kit Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Gist Mutation Detection Kit Market size was valued at USD 478.0 Million in 2024 and is poised to grow from USD 529.15 Million in 2025 to USD 1193.32 Million by 2033, growing at a CAGR of 10.7% during the forecast period (2026-2033).
Thermo Fisher Scientific’s acquisition of a niche molecular‑diagnostics firm and Roche’s partnership with Illumina to integrate next‑generation sequencing into GIST panels illustrate how incumbents are consolidating capabilities, while QIAGEN’s launch of an automated GIST mutation detection kit showcases a technology‑driven differentiation strategy that intensifies competition and accelerates market adoption. 'F. Hoffmann-La Roche Ltd.', 'QIAGEN N.V.', 'Thermo Fisher Scientific Inc.', 'Agilent Technologies, Inc.', 'Illumina, Inc.', 'Danaher Corporation', 'Bio-Rad Laboratories, Inc.', 'Merck KGaA', 'Guardant Health, Inc.', 'Myriad Genetics, Inc.', 'NeoGenomics, Inc.', 'Natera, Inc.', 'GenScript Biotech Corporation', 'BGI Genomics Co., Ltd.', 'Sysmex Corporation', 'Oxford Nanopore Technologies plc', 'Pacific Biosciences of California, Inc.', 'Integrated DNA Technologies, Inc.', 'Invivoscribe, Inc.', 'Biocartis Group NV'
The expanding integration of precision medicine into oncology workflows drives laboratories to seek robust mutation detection solutions, prompting increased procurement of GIST kits that enable rapid, multiplexed analysis of clinically relevant alterations, thereby supporting personalized treatment decisions and improving patient outcomes across diverse care settings. These kits also streamline assay development, reduce turnaround times, and facilitate compliance with emerging biomarker guidelines, which collectively reinforce and foster a long‑term strategic value of adopting such technologies within research and diagnostic laboratories worldwide.
Precision Oncology Integration: The adoption of comprehensive genomic profiling in oncology clinics is driving demand for GIST mutation detection kits, as clinicians seek to tailor therapies to individual tumor signatures, improving response rates and reducing adverse effects, while pharmaceutical partners leverage these kits to identify suitable patient cohorts for targeted drug trials, fostering a feedback loop that accelerates innovation and reinforces the clinical value proposition of precise mutation diagnostics across diverse healthcare settings through collaborative research networks and real‑world evidence generation globally continually.
Why does North America Dominate the Global GIST Mutation Detection Kit Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
